Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
Baxter
Mallinckrodt
Express Scripts

Last Updated: August 11, 2022

Investigational Drug Information for Vaborbactam


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Vaborbactam?

Vaborbactam is an investigational drug.

There have been 5 clinical trials for Vaborbactam. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Infections, Infection, and Pyelonephritis. The leading clinical trial sponsors are Department of Health and Human Services, Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), and Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.).

There are twenty-eight US patents protecting this investigational drug and two hundred and thirty-three international patents.

Recent Clinical Trials for Vaborbactam
TitleSponsorPhase
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaMelinta Therapeutics, Inc.Phase 3
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy VolunteersBiomedical Advanced Research and Development AuthorityPhase 1
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy VolunteersRempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Phase 1

See all Vaborbactam clinical trials

Clinical Trial Summary for Vaborbactam

Top disease conditions for Vaborbactam
Top clinical trial sponsors for Vaborbactam

See all Vaborbactam clinical trials

US Patents for Vaborbactam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vaborbactam See Plans and Pricing Cyclic boronic acid ester derivatives and methods of making the same Rempex Pharmaceuticals, Inc. (San Diego, CA) See Plans and Pricing
Vaborbactam See Plans and Pricing Beta-lactamase inhibitors Novartis AG (Basel, CH) See Plans and Pricing
Vaborbactam See Plans and Pricing Beta-lactamase inhibitors and uses thereof ARIXA PHARMACEUTICALS, INC. (Palo Alto, CA) See Plans and Pricing
Vaborbactam See Plans and Pricing Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams ARIXA PHARMACEUTICALS, INC. (Palo Alto, CA) See Plans and Pricing
Vaborbactam See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Vaborbactam See Plans and Pricing Pharmaceutical compositions comprising cyclic boronic acid ester derivatives REMPEX PHARMACEUTICALS, INC. (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vaborbactam

Drugname Country Document Number Estimated Expiration Related US Patent
Vaborbactam Australia AU2011289615 2030-08-10 See Plans and Pricing
Vaborbactam Brazil BR112013003045 2030-08-10 See Plans and Pricing
Vaborbactam Canada CA2807546 2030-08-10 See Plans and Pricing
Vaborbactam Chile CL2013000399 2030-08-10 See Plans and Pricing
Vaborbactam China CN103180328 2030-08-10 See Plans and Pricing
Vaborbactam Colombia CO6680667 2030-08-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.